NeoGenomics, Inc. (NASDAQ:NEO) has been given a consensus recommendation of “Hold” by the eleven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $18.33.
A number of research firms have weighed in on NEO. Canaccord Genuity lifted their price objective on NeoGenomics from $23.00 to $24.00 in a report on Tuesday, March 13th. Scotiabank boosted their target price on NeoGenomics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, March 13th. ValuEngine downgraded NeoGenomics from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Finally, Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, March 1st.
Several institutional investors and hedge funds have recently made changes to their positions in NEO. Teacher Retirement System of Texas acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $182,000. Howland Capital Management LLC boosted its holdings in shares of NeoGenomics by 67.6% in the 4th quarter. Howland Capital Management LLC now owns 21,782 shares of the medical research company’s stock worth $193,000 after acquiring an additional 8,782 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $235,000. Campbell & CO Investment Adviser LLC boosted its holdings in shares of NeoGenomics by 64.0% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 21,544 shares of the medical research company’s stock worth $240,000 after acquiring an additional 8,404 shares in the last quarter. Finally, Aperio Group LLC acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $243,000. 84.63% of the stock is currently owned by institutional investors and hedge funds.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $67.79 million for the quarter, compared to the consensus estimate of $66.32 million. NeoGenomics had a positive return on equity of 4.34% and a negative net margin of 1.37%. The company’s quarterly revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 earnings per share. equities analysts expect that NeoGenomics will post 0.09 EPS for the current year.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.